Oligometastatic Prostate Cancer Should Be Studied and Treated Differently to High-volume Disease. Con: The Underlying Biology is the Same, So They Should Not Be Treated Differently.
暂无分享,去创建一个
[1] A. Zwinderman,et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. , 2019, European urology.
[2] M. Parmar,et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial , 2018, The Lancet.
[3] R. DiPaola,et al. Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. , 2018, European urology.
[4] David F Jarrard,et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] M. Sydes,et al. 'Thursday's child has far to go'-interpreting subgroups and the STAMPEDE trial. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] Y. Park,et al. Abiraterone plus Prednisone in Metastatic, Castration‐Sensitive Prostate Cancer , 2017, The New England journal of medicine.
[7] M. Parmar,et al. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy , 2017, The New England journal of medicine.
[8] R. Laing,et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial , 2016, The Lancet.
[9] M. Parmar,et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data , 2016, The Lancet. Oncology.
[10] David F Jarrard,et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. , 2015, The New England journal of medicine.
[11] Donna L Berry,et al. Intermittent versus continuous androgen deprivation in prostate cancer. , 2013, The New England journal of medicine.
[12] Kim-Anh Do,et al. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] I. Thompson,et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. , 1998, The New England journal of medicine.